AbbVie Presents Long-Term Data Further Supporting the Effica

Three ongoing, randomized, double-blind, multicenter Phase 3 studies demonstrated the long-term efficacy and safety profile of RINVOQ® in treating moderate to severe atopic dermatitis based on...

Related Keywords

United States , Berlin , Germany , Japan , Japanese , Mudra Kapoor , J Clin Dermatol , Facebook , Youtube , Exchange Commission , Allergan , Abbvie Ltd , Linkedin , Twitter , Instagram , European Academy Of Dermatology , European Academy , Emergent Adverse Events , Global Assessment , Atopic Dermatitis , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports , Upadacitinib Through , Moderate To Severe Atopic Dermatitis , Clinical Trial , Global Epidemiology , Ann Nutr Metab , Rev Dis Primers , Adolescents With Uncontrolled Moderate , Severe Atopic Dermatitis , Term Efficacy , Results Through Week , Label Extension Trial , Healthcare Claims Data , Accessed August , Markets ,